Shares of Quidel Co. (NASDAQ:QDEL) have earned an average recommendation of “Buy” from the nine analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $54.20.
QDEL has been the topic of several analyst reports. Canaccord Genuity reaffirmed a “buy” rating and issued a $48.00 price objective on shares of Quidel in a research report on Wednesday, October 25th. Barclays upped their price objective on Quidel from $45.00 to $49.00 and gave the company an “overweight” rating in a research report on Thursday, November 2nd. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Quidel in a research report on Friday, November 3rd. Zacks Investment Research cut Quidel from a “buy” rating to a “hold” rating in a research report on Tuesday, November 7th. Finally, BidaskClub raised Quidel from a “sell” rating to a “hold” rating in a research report on Saturday, December 2nd.
In other news, Director Jack W. Schuler sold 4,000 shares of the stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $44.60, for a total transaction of $178,400.00. Following the transaction, the director now directly owns 3,365,553 shares of the company’s stock, valued at approximately $150,103,663.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Douglas C. Bryant sold 12,000 shares of the stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $46.82, for a total value of $561,840.00. Following the transaction, the chief executive officer now directly owns 286,493 shares in the company, valued at $13,413,602.26. The disclosure for this sale can be found here. Insiders have sold a total of 370,260 shares of company stock worth $15,293,980 over the last three months. Insiders own 22.00% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in QDEL. Teachers Advisors LLC raised its holdings in Quidel by 10.9% in the 2nd quarter. Teachers Advisors LLC now owns 54,932 shares of the company’s stock worth $1,491,000 after purchasing an additional 5,395 shares during the period. TIAA CREF Investment Management LLC raised its holdings in Quidel by 1.1% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 99,227 shares of the company’s stock worth $2,693,000 after purchasing an additional 1,062 shares during the period. Northern Trust Corp raised its holdings in Quidel by 6.9% in the 2nd quarter. Northern Trust Corp now owns 377,707 shares of the company’s stock worth $10,250,000 after purchasing an additional 24,453 shares during the period. Vanguard Group Inc. raised its holdings in Quidel by 3.2% in the 2nd quarter. Vanguard Group Inc. now owns 2,195,101 shares of the company’s stock worth $59,575,000 after purchasing an additional 68,549 shares during the period. Finally, Voya Investment Management LLC raised its holdings in Quidel by 11.1% in the 2nd quarter. Voya Investment Management LLC now owns 13,636 shares of the company’s stock worth $370,000 after purchasing an additional 1,366 shares during the period. 92.07% of the stock is currently owned by hedge funds and other institutional investors.
Quidel (NASDAQ:QDEL) traded up $0.77 during mid-day trading on Friday, reaching $45.87. The company had a trading volume of 191,900 shares, compared to its average volume of 308,766. The company has a market cap of $1,559.44, a PE ratio of -305.78, a PEG ratio of 1.48 and a beta of 1.02. Quidel has a fifty-two week low of $20.43 and a fifty-two week high of $49.47. The company has a debt-to-equity ratio of 0.70, a current ratio of 6.28 and a quick ratio of 5.68.
COPYRIGHT VIOLATION WARNING: This piece was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/20/quidel-co-qdel-receives-54-20-consensus-pt-from-brokerages.html.
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.
Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.